Clayton 2017 — Ambulatory BP Monitoring of Bremelanotide

Blood Pressure Monitoring·April 1, 2017

William B. White, Martin G. Myers, Robert Jordan, Johna Lucas

Summary

Evaluated the usefulness of ambulatory blood pressure monitoring to assess cardiovascular safety of the melanocortin receptor agonist bremelanotide.

Study Details

Study Design

Randomized, double-blind, placebo-controlled ambulatory BP study

Indication

Female sexual dysfunction

Intervention

0.75 / 1.25 / 1.75 mg subcutaneous

Species

Human

Sample Size

397 subjects

Risk of Bias Assessment

Industry-sponsored